Implantable defibrillators versus medical therapy for cardiac channelopathies

David A. Mcnamara; Jeffrey J. Goldberger; Mark A. Berendsen; Mark D. Huffman

doi:10.1002/14651858.CD011168

Implantable defibrillators versus medical therapy for cardiac channelopathies

David A. Mcnamara^*, Jeffrey J. Goldberger, Mark A. Berendsen, Mark D. Huffman

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows: To compare the effectiveness of ICDs with antiarrhythmic drugs, placebo, or usual care in reducing the risk of all-cause mortality, cardiovascular mortality, and adverse events in individuals at increased risk of sudden cardiac death due to cardiac ion channelopathies, including congenital long QT syndrome, congential short QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia.

Original language	English (US)
Article number	CD011168
Journal	Cochrane Database of Systematic Reviews
Volume	2014
Issue number	6
DOIs	https://doi.org/10.1002/14651858.CD011168
State	Published - Jun 25 2014

Funding

Dr. Mark Huffman receives grant support from the National Heart, Lung, and Blood Institute and World Heart Federation through unrestricted educational grants from AstraZeneca and Boehringer Ingelheim on research and a research training program, respectively, both of which are unrelated to this review

ASJC Scopus subject areas

Pharmacology (medical)

Access to Document

10.1002/14651858.CD011168

Cite this

@article{8df15fe0e1ed4e84aaa36b04cdc375aa,

title = "Implantable defibrillators versus medical therapy for cardiac channelopathies",

abstract = "This is the protocol for a review and there is no abstract. The objectives are as follows: To compare the effectiveness of ICDs with antiarrhythmic drugs, placebo, or usual care in reducing the risk of all-cause mortality, cardiovascular mortality, and adverse events in individuals at increased risk of sudden cardiac death due to cardiac ion channelopathies, including congenital long QT syndrome, congential short QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia.",

author = "Mcnamara, {David A.} and Goldberger, {Jeffrey J.} and Berendsen, {Mark A.} and Huffman, {Mark D.}",

note = "Funding Information: Dr. Mark Huffman receives grant support from the National Heart, Lung, and Blood Institute and World Heart Federation through unrestricted educational grants from AstraZeneca and Boehringer Ingelheim on research and a research training program, respectively, both of which are unrelated to this review Publisher Copyright: {\textcopyright} 2014 The Cochrane Collaboration.",

year = "2014",

month = jun,

day = "25",

doi = "10.1002/14651858.CD011168",

language = "English (US)",

volume = "2014",

journal = "Cochrane Database of Systematic Reviews",

issn = "1361-6137",

publisher = "John Wiley and Sons Ltd",

number = "6",

}

TY - JOUR

T1 - Implantable defibrillators versus medical therapy for cardiac channelopathies

AU - Mcnamara, David A.

AU - Goldberger, Jeffrey J.

AU - Berendsen, Mark A.

AU - Huffman, Mark D.

N1 - Funding Information: Dr. Mark Huffman receives grant support from the National Heart, Lung, and Blood Institute and World Heart Federation through unrestricted educational grants from AstraZeneca and Boehringer Ingelheim on research and a research training program, respectively, both of which are unrelated to this review Publisher Copyright: © 2014 The Cochrane Collaboration.

PY - 2014/6/25

Y1 - 2014/6/25

N2 - This is the protocol for a review and there is no abstract. The objectives are as follows: To compare the effectiveness of ICDs with antiarrhythmic drugs, placebo, or usual care in reducing the risk of all-cause mortality, cardiovascular mortality, and adverse events in individuals at increased risk of sudden cardiac death due to cardiac ion channelopathies, including congenital long QT syndrome, congential short QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia.

AB - This is the protocol for a review and there is no abstract. The objectives are as follows: To compare the effectiveness of ICDs with antiarrhythmic drugs, placebo, or usual care in reducing the risk of all-cause mortality, cardiovascular mortality, and adverse events in individuals at increased risk of sudden cardiac death due to cardiac ion channelopathies, including congenital long QT syndrome, congential short QT syndrome, Brugada syndrome and catecholaminergic polymorphic ventricular tachycardia.

UR - http://www.scopus.com/inward/record.url?scp=85048469735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048469735&partnerID=8YFLogxK

U2 - 10.1002/14651858.CD011168

DO - 10.1002/14651858.CD011168

M3 - Article

AN - SCOPUS:85048469735

SN - 1361-6137

VL - 2014

JO - Cochrane Database of Systematic Reviews

JF - Cochrane Database of Systematic Reviews

IS - 6

M1 - CD011168

ER -

Implantable defibrillators versus medical therapy for cardiac channelopathies

Abstract

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this